基础医学与临床 ›› 2019, Vol. 39 ›› Issue (10): 1494-1498.

• 短篇综述 • 上一篇    下一篇

奥贝胆酸的研究进展

邢苗苗,张晓燕,管又飞   

  1. 大连医科大学
  • 收稿日期:2018-11-28 修回日期:2019-03-25 出版日期:2019-10-05 发布日期:2019-09-25
  • 通讯作者: 管又飞 E-mail:guanyf@dmu.edu.cn
  • 基金资助:
    代谢性核受体与肾脏水和溶质转运调节;糖代谢稳态调节基因的转录及转录后调控机制;前列腺素E2受体EP4在血管稳态维持及重塑中的作用;大连市高层次人才创新支持计划

Research progress of obeticholic acid

  • Received:2018-11-28 Revised:2019-03-25 Online:2019-10-05 Published:2019-09-25

摘要: 奥贝胆酸是一种新型选择性FXR激动剂,在调节胆汁酸代谢及糖脂代谢中发挥着重要的作用,是原发性胆汁性肝硬化以及非酒精性脂肪肝的新型候选药物。奥贝胆酸可通过抑制纤维化进程和抑制炎性反应过程从而缓解疾病。

关键词: 奥贝胆酸, FXR, 原发性胆汁性肝硬化, 非酒精性脂肪肝

Abstract: Obeticholic acid is a novel selective FXR agonist that plays an important role in regulating bile acid metabolism, as well as glucose and lipid metabolism. It is a new drug candidate for primary biliary cirrhosis and nonalcoholic fatty liver disease. A series of studies have shown that obeticholic acid can alleviate the disease by inhibiting the progression of fibrosis and inhibiting the inflammatory process.

Key words: obeticholic ocid, FXR, primary biliary cholangitis, non-alcoholic steatohepatitis